Medical device company ResMed (NYSE:RMD) met Wall Streets revenue expectations in Q3 CY2025, with sales up 9.1% year on year ...
StockStory.org on MSN
ResMed (NYSE:RMD) Reports Q3 In Line With Expectations
Medical device company ResMed (NYSE:RMD) in Q3 CY2025, with sales up 9.1% year on year to $1.34 billion. Its non-GAAP profit ...
12d
ResMed Inc (RMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations
ResMed Inc (RMD) reports a robust quarter with 9% revenue growth, strategic product launches, and expansion in key markets ...
Resmed Inc.’s RMD adjusted earnings per share (EPS) in the first quarter of fiscal 2026 were $2.55, up 15.9% year over year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback